ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
60,803.88
0.01%
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs Yen
155.785
0.00%
Brent Oil
82.585
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Janux Therapeutics Inc (JANX)

  7. Janux Therapeutics Inc (JANX) ニュース

JANX

Janux Therapeutics (JANX)

Janux Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:JANX
日付受信時刻ニュースソース見出しコード企業名
2024/05/0822 : 13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:JANXJanux Therapeutics Inc
2024/05/0805 : 01Business WireJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
2024/03/0906 : 47Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:JANXJanux Therapeutics Inc
2024/03/0906 : 23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:JANXJanux Therapeutics Inc
2024/03/0906 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2024/03/0906 : 01Business WireJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
2024/03/0107 : 30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
2024/03/0107 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2024/02/2915 : 22Business WireJanux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
2024/02/2911 : 55Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:JANXJanux Therapeutics Inc
2024/02/2907 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2024/02/2811 : 50Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
2024/02/2807 : 23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2024/02/2807 : 00Business WireJanux Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:JANXJanux Therapeutics Inc
2024/02/2706 : 05Business WireJanux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid TumorsNASDAQ:JANXJanux Therapeutics Inc
2024/02/2022 : 00Business WireJanux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008NASDAQ:JANXJanux Therapeutics Inc
2024/02/1006 : 31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
2024/02/0206 : 15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
2024/01/0823 : 00Business WireJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific OfficerNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406 : 53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406 : 49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406 : 47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406 : 45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2023/11/0806 : 19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:JANXJanux Therapeutics Inc
2023/11/0806 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2023/11/0806 : 01Business WireJanux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
2023/09/0807 : 14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
2023/08/1505 : 33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:JANX

最近閲覧した銘柄

AMEX
SPY
SPDR S&P 500
NYSE
NKE
Nike
CCOM
US500
US 500
NASDAQ
MSFT
Microsoft
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
AXP
American Express
FX
USDEUR
US Dollar vs Euro
NASDAQ
TSLA
Tesla
PM
XAUUSD
Gold vs US Dollar
AMEX
XLV
Health Care Select Sector
SPI
SP500
S&P 500
AMEX
XLE
Energy Select Sector SPDR
COIN
BTCUSD
Bitcoin
NYSE
BAC
Bank of America
USI
USTECH100
US Tech 100
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有